Advertisement
Canada markets open in 3 hours 45 minutes

  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CAD/USD

    0.7306
    -0.0015 (-0.20%)
     

  • CRUDE OIL

    78.52
    +0.04 (+0.05%)
     

  • Bitcoin CAD

    87,914.28
    -1,282.37 (-1.44%)
     

  • CMC Crypto 200

    1,333.77
    -31.36 (-2.30%)
     

  • GOLD FUTURES

    2,323.60
    -7.60 (-0.33%)
     

  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • NASDAQ futures

    18,174.50
    -21.00 (-0.12%)
     

  • VOLATILITY

    13.54
    +0.05 (+0.37%)
     

  • FTSE

    8,298.43
    +84.94 (+1.03%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6789
    -0.0003 (-0.04%)
     

Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference

Agile Therapeutics, Inc.
·1 min read
Agile Therapeutics, Inc.
Agile Therapeutics, Inc.

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Chairman and Chief Executive Officer Al Altomari will present a corporate overview at the conference on Monday, December 5 at 3:20 p.m. ET.

The RHK Capital Disruptive Growth Conference webcast will be available on the investor relations page of the Company’s website at https://ir.agiletherapeutics.com/events-and-presentations. The replay of the webcast will be archived on the website for approximately 30 days.

To learn more or submit a registration request for the conference, visit http://disruptnyc.com/.

ADVERTISEMENT

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website, Twitter account (@agilether), and LinkedIn account.

Contact:
Matt Riley
Head of Investor Relations & Corporate Communications 
mriley@agiletherapeutics.com